in the investor update presentation, in the section...

in the investor update presentation, in the section commercialisation is well advanced.

in the battery section has a tick for battery anode enhancement surface silicon and battery anode enhancement silicon composites.
in the life science section, has a tick for ivd reagents, activated particle kits for poc/ivd, poc lateral flow test stripe and a tick for POC FEE FOR SERVICE - haven't seen that in any quarterlies.

then in the next page point5. January 2019 - diagnostics partner Ellume, deploys Antebind to GSK on respiratory care and nyse- listed Qiagen TB test.

maybe we'll see something in the coming quarterly???